Can a common drug stop chemo weight loss in stomach cancer?

NCT ID NCT07581405

Not yet recruiting Symptom relief Sponsor: University of Illinois at Chicago Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a low dose of olanzapine, a drug often used for nausea, can help gastric cancer patients avoid weight loss and keep their appetite during chemotherapy before surgery. About 26 adults with stomach cancer will be randomly assigned to receive olanzapine or standard care alone. The goal is to see if olanzapine improves nutrition and quality of life during treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Olanzapine
What this could lead to: If it works, this could offer a simple way to help gastric cancer patients keep their weight and appetite up during chemotherapy.
What could go wrong: This is a small, early-phase trial with only 26 people, so results may not apply widely. Olanzapine can cause side effects like drowsiness or increased blood sugar.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTRIC ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gastric adenocarcinoma gastric cancer gastric neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GASTRIC ADENOCARCINOMA GASTRIC CANCER

Contacts and locations

Locations

University of Illinois Cancer Center

Chicago, Illinois, 60612, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.